Shawn G. Hansen is an intellectual property partner based in our Los Angeles office. Shawn also maintains an office in our San Francisco office to work with clients and handle matters in Northern California. Shawn has a successful track record over nearly two decades of representing emerging and established companies in litigation of intellectual property cases in federal courts throughout the United States. His litigation experience includes trials, arbitrations, and foreign discovery, including depositions in United States consular facilities in Japan. He also represents clients in inter partes review proceedings before the Patent Trial and Appeal Board of the United States Patent & Trademark Office. Clients value his distinct acumen for grasping what matters in their businesses and for crafting and executing intellectual property strategies that align with their specific business objectives and circumstances. In selecting Shawn for a critical role, one client said, “I trust Shawn immensely to get this right and have a fair dose of pragmatism and decisiveness.” Shawn also is known as a collegial teammate, described by one colleague as “smart, energetic, insightful, organized and fun to work with.”
I help clients in the life sciences, technology, and media industries develop and execute IP strategies to serve their business objectives across the spectrum from bet-the-company litigation to transactional due diligence to research and development.
Represented Cedars-Sinai Medical Center in prosecuting, licensing, and enforcing patent rights on methods of treating irritable bowel syndrome (“IBS”), a chronic condition affecting more than 15% of the general population. Cedars-Sinai doctors invented groundbreaking treatments for IBS, and the NP team helped Cedars-Sinai patent these discoveries and license them to Salix Pharmaceuticals, a wholly-owned subsidiary of Bausch Health Companies Inc. After Actavis Laboratories FL, Inc. sought FDA approval to market a generic competitor drug, NP represented Cedars-Sinai in litigation with its licensees against the infringing generic competitor. That litigation recently was resolved under confidential terms that assure Cedars-Sinai’s patent rights will be protected through their expiration.
Los Angeles Daily Journal | October 10, 2017
Los Angeles IP litigation partner Shawn Hansen is quoted in this article about drug maker Amgen Inc.’s request for a federal judge to invalidate patents claimed by a rival company so it can create a generic, less expensive version of a popular cancer drug.
Law360 | May 22, 2017
Los Angeles IP litigation partner Shawn Hansen is quoted in the following articles discussing the Supreme Court’s decision in the patent case TC Heartland LLC v. Kraft Food Brands Group LLC, which limits where plaintiffs can file patent lawsuits.
The New York Times | May 22, 2017
Los Angeles IP litigation partner Shawn Hansen is quoted in the following articles discussing the Supreme Court’s decision in the patent case TC Heartland LLC v. Kraft Food Brands Group LLC, which limits where plaintiffs can file patent lawsuits.
Los Angeles/San Francisco Daily Journal | February 15, 2017
Los Angeles IP litigation partner Shawn Hansen authored this column about an upcoming case in the U.S. Supreme Court that will deal with Biologics Price Competition and Innovation Act of 2009 (BPCIA), which was enacted as part of the Affordable Care Act (ACA).
University of California, Hastings College of the Law, J.D., Senior Articles Editor, Hastings Communications & Entertainment Law Journal
Brigham Young University, B.S., Human Biology
California
U.S. Court of Appeals, Federal Circuit
U.S. Court of Appeals, Ninth Circuit
U.S. District Court, Northern District of California
U.S. District Court, Central District of California
U.S. District Court, Southern District of California
U.S. Patent and Trademark Office
Shawn has been recommended in The Legal 500 United States 2017 editorial for Intellectual property - Trade secrets (litigation and non-contentious matters).
